Reuters logo
BRIEF-Amag Pharmaceuticals enters into an agreement to develop and commercialize Rekynda
January 9, 2017 / 1:23 PM / 10 months ago

BRIEF-Amag Pharmaceuticals enters into an agreement to develop and commercialize Rekynda

Jan 9 (Reuters) - Amag Pharmaceuticals Inc

* Entered into an agreement for exclusive North American rights to develop and commercialize Rekynda

* Anticipated filing date in U.S. for NDA for Rekynda is in early 2018, with an anticipated approval and launch by early 2019

* Under terms of license agreement, Amag will pay to Palatin $60 million of total upfront consideration

* To reimburse palatin for up to $25 million of ongoing development expenses incurred by Palatin related to development of Rekynda in 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below